Salmeterol Xinafoate: all 98 studies that test it
Page 1 of 1. Open to participants first (2), then studies with results posted, then the rest; newest registration first within each.
- Salmeterol Effect on Exercise PerformanceRecruitingNCT06655012Not applicable
- A Study to Evaluate the Efficacy and Safety of QVM149 (Indacaterol Acetate / Glycopyrronium Bromide / Mometasone Furoate) Versus Salmeterol Xinafoate/Fluticasone Propionate in Children From 12 Years to Less Than 18 Years of Age With Asthma.RecruitingNCT05776927Phase 3
- A 24-Week Treatment Study to Compare Standard of Care Versus the eMDPI DS in Participants 13 Years or Older With AsthmaCompletedNCT04677959Phase 4Results posted
- A 24-week Study to Compare Umeclidinium/Vilanterol (UMEC/VI), UMEC and Salmeterol in Subjects With Chronic Obstructive Pulmonary Disease (COPD)CompletedNCT03034915Phase 4Results posted
- Study of Fluticasone Propionate Multidose Dry Powder Inhaler Compared With Fluticasone Propionate/Salmeterol Multidose Dry Powder InhalerCompletedNCT02980133Phase 3Results posted
- Single Blind Cross-over Dose Response Study in Subjects of Two Inhalers of Salmeterol and Fluticasone PropionateCompletedNCT02232087Phase 1Results posted
- A 3 Way Cross-over Study Evaluating the Effects of ADOAIR Twice Daily Plus Tiotropium Bromide Once Daily Compared With the Individual Treatments of Japanese SubjectsCompletedNCT01751113Phase 4Results posted
- Effects of Salmeterol on Autonomic Nervous SystemCompletedNCT01536587Phase 4Results posted
- Interactive Acute Smooth Muscle Effects of Salmeterol and Fluticasone in the AirwayCompletedNCT01231230Not applicableResults posted
- Sub-Sensitivity to Long-Acting Bronchodilators (LABA)CompletedNCT01117116Not applicableResults posted
- Chronic Obstructive Pulmonary Disease (COPD) Post-hospitalization StudyCompletedNCT01110200Phase 4Results posted
- Validation of a New Shortness of Breath With Daily Activities Questionnaire in Patients With Chronic Obstructive Pulmonary DiseaseCompletedNCT00984659Phase 4Results posted
- Inhaled Corticosteroid Withdrawal in Patients With Chronic Obstructive Pulmonary DiseaseCompletedNCT00975195Phase 4Results posted
- A 24-Week Study to Evaluate the Safety and Efficacy of ADVAIR DISKUS® Inhaler 250/50mcg Plus SPIRIVA HANDIHALER® Inhaler Versus SPIRIVA HANDIHALER® Inhaler Plus Placebo DISKUS® Inhaler in Subjects With Chronic Obstructive Pulmonary Disease (COPD).CompletedNCT00784550Phase 4Results posted
- The Effects of Montelukast on Smokers With AsthmaCompletedNCT00712335Phase 4Results posted
- Study to Determine the Onset of Action of Indacaterol in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)CompletedNCT00669617Phase 3Results posted
- Tiotropium/Salmeterol Inhalation Powder in COPDTerminatedNCT00668772Phase 3Results posted
- Efficacy and Safety Comparison of Tiotropium Daily + Salmeterol Daily or Twice Daily Versus Tiotropium Daily in Patients With COPDCompletedNCT00662792Phase 3Results posted
- A Crossover Study to Determine the 24 Hour Lung Function Profile of Indacaterol in Patients With Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD)CompletedNCT00622635Phase 3Results posted
- Study of Indacaterol Dosed in the Evening in Patients With Chronic Obstructive Pulmonary Disease (COPD)CompletedNCT00615030Phase 3Results posted
- How Different Beta-2 Receptor Genotypes Affect an Asthmatic's Response to Regular Salmeterol TreatmentCompletedNCT00595361Not applicableResults posted
- Tiotropium Once Daily 18 Mcg Versus Salmeterol Twice Daily 50 Mcg on Time to First Exacerbation in COPD Patients.CompletedNCT00563381Phase 4Results posted
- Safety of Exercise and High-dose Salbutamol in Patients With Chronic Obstructive Pulmonary Disease (COPD) Receiving Therapeutic Doses of Indacaterol (QAB 149) and SalmeterolCompletedNCT00531050Phase 2Results posted
- Effect of Tiotropium Plus Salmeterol vs. Fluticasone/Salmeterol on Static Lung Volumes and Exercise Endurance in COPDCompletedNCT00530842Phase 4Results posted
- Study Of RV-39 In Patients Who Also Have AsthmaTerminatedNCT00503009Phase 4Results posted
- A 12-Week Study To Assess The Safety Of Fluticasone Propionate/Salmeterol 100/50 Hydrofluoroalkane (HFA) Versus Fluticasone Propionate 100 HFA In Children With AsthmaCompletedNCT00441441Phase 3Results posted
- Dose Ranging Study for Indacaterol in Japanese Asthma PatientsCompletedNCT00403754Phase 2Results posted
- Childhood Asthma Research and Education (CARE) Network Trial - Best Add-On Therapy Giving Effective Response (BADGER)CompletedNCT00395304Phase 3Results posted
- Bone Mineral Density Study In Patients With Chronic Obstructive Pulmonary Disease. DISKUS® Inhaler is a Trademark of the GSK Group of Companies.CompletedNCT00355342Phase 4Results posted
- Seretide Versus Flixotide In Asthmatic Children Not Controlled By Inhaled CorticosteroidsCompletedNCT00353873Phase 4Results posted
- Study Of Allergic Rhinitis In Patients Who Also Have AsthmaCompletedNCT00296491Phase 4Results posted
- Montelukast Compared With Placebo and Salmeterol in Exercise-Induced Bronchoconstriction (0476-316)CompletedNCT00245570Phase 3Results posted
- The Effect of Salmeterol on Eosinophil (EOS) FunctionCompletedNCT00214019Not applicableResults posted
- Asthma Clinical Research Network (ACRN) Trial - Long-Acting Beta Agonist Response by Genotype (LARGE)CompletedNCT00200967Phase 3Results posted
- The Leukotriene Modifier Or Corticosteroid or Corticosteroid-Salmeterol TrialCompletedNCT00156819Phase 4Results posted
- A Study Measuring Asthma Control In Pediatric And Adolescent Subjects Whose Asthma Is Worsened By Activity Or ExerciseCompletedNCT00118716Phase 4Results posted
- Mechanisms of Adverse Effects of Long-Acting Beta-Agonists in AsthmaStatus unknownNCT04503460Phase 4
- Generation of Biological Samples Positive to Salmeterol for Anti-Doping ControlCompletedNCT04195867Phase 1
- Clinical Endpoint Bioequivalence Study of Fluticasone Propionate & Salmeterol Xinafoate (100μg/50μg)CompletedNCT03535870Not applicable
- A Double Blind Open Label Comparator Study to Compare Treatments in 4 to 11 Year Old Patients With AsthmaCompletedNCT02680561Phase 1
- Clinical Endpoint Bioequivalence Study for Fluticasone Propionate and Salmeterol XinafoateCompletedNCT02649478Not applicable
- Pharmacological Properties of SalmeterolCompletedNCT02558088Phase 4
- Exhaled NO Based Treatment of Chronic Obstructive Pulmonary Disease (COPD), ICS/LABA Versus LAMAStatus unknownNCT02546349Phase 4
- Bioequivalence Study of Synflutide HFA Inhaler and Seretide Evohaler in Healthy Volunteers With Charcoal BlockCompletedNCT02466503Phase 1
- Bioequivalence Study of Synflutide HFA Inhaler and Seretide Evohaler in Healthy Volunteers Without Charcoal BlockCompletedNCT02466347Phase 1
- Study to Determine the Pharmacokinetics and Tolerability of Fluticasone Propionate MDPI and Fluticasone Propionate/Salmeterol MDPI Compared to High Strength FLOVENT® DISKUS® and ADVAIR® DISKUS® in Patients With Persistent Asthma 12 Years of Age and OlderCompletedNCT02437604Phase 1
- Relative Bioavailability of Tiotropium and Salmeterol After Inhalation of a Fixed Combined Dose Compared to Monocomponents in Healthy Male VolunteersCompletedNCT02254174Phase 1
- Free Combinations of Tiotropium Inhalation Powder Capsule + Salmeterol Metered Dose Inhaler, Tiotropium Inhalation Powder Capsule and Salmeterol Metered Dose Inhaler in Patients With Chronic Obstructive Pulmonary Disease (COPD)CompletedNCT02242253Phase 2
- Efficacy, Pharmacokinetics and Safety Comparison of Salmeterol Inhalation Powder Administered Via the HandiHaler® 2 and Serevent® Diskus® in Patients With Chronic Obstructive Pulmonary Disease (COPD)CompletedNCT02242227Phase 2
- Nitric Oxyde Concentration in Chronic Obstructive Pulmonary Disease Patients - SANOB StudyCompletedNCT01853787Phase 4
- Dose Ranging StudyCompletedNCT01802723Phase 2
- Dose-ranging StudyCompletedNCT01712451Phase 2
- Phase I Pharmacokinetic Study (SALBLOCK)CompletedNCT01564199Phase 1
- A Single Centre Study in Healthy Volunteers to Optimise the Rotacap Formulation and ROTAHALER Device for Delivery of Fluticasone Propionate/SalmeterolCompletedNCT01540708Phase 1
- Management of Asthma in School-age Children on TherapyCompletedNCT01526161Phase 4
- Fluticasone and Salmeterol in Allergic RhinitisCompletedNCT01388595Phase 4
- Sunovion Brovana Versus Serevent Inspiratory Capacity High Resolution Computed TomographyStatus unknownNCT01361984Phase 4
- Effects of Anticholinergic or Long-Acting Beta 2 Agonist on FeNO and Pulmonary Function in SCIStatus unknownNCT01355991Phase 1
- Effect of Salmeterol on Fluid Clearance From Alveolar-Capillary Membrane in COPD PatientsCompletedNCT01271556Not applicable
- The Efficacy and Safety of Salmeterol/Fluticasone Propionate vs Atropium/Albuterol in Patients COPDStatus unknownNCT01243788Phase 4
- Effect of an Inhaled Glucocorticoid-long-acting Beta Adrenergic Agonist on Endothelial Function in COPDWithdrawnNCT01209715Phase 2
- A Non- Inferiority Comparative Study Between Seretide® and Salmeterol/Fluticasone Eurofarma in Patients with AsthmaCompletedNCT01202097Phase 3
- Study of Salmeterol (SN408D) for Adult AsthmaCompletedNCT00950794Phase 4
- Concentrations of Salmeterol in Blood and UrineStatus unknownNCT00914901Phase 4
- Impact of Fluticasone and Salmeterol on Airway Dendritic Cells (DCs) in SmokersCompletedNCT00908362Phase 1
- Clinical Outcomes of Tiotropium Plus Fluticasone Propionate/Salmeterol Compared With Tiotropium for Chronic Obstructive Pulmonary Disease (COPD) in KoreaCompletedNCT00864812Phase 4
- Fluticasone/Salmeterol (FP/SM) Versus Double the Dose Fluticasone (FP) in Patients With Mild to Moderate AsthmaCompletedNCT00830505Phase 4
- Effect of Salmeterol on Brain-Derived Neurotrophic Factor (BDNF) Concentrations in AsthmaCompletedNCT00736801Not applicable
- Tiotropium and Salmeterol PK Study in COPD PatientsCompletedNCT00673478Phase 3
- Add-on Salmeterol Versus Montelukast in Arg/Arg-16 AsthmaticsCompletedNCT00655616Not applicable
- Tiotropium for Smoking Asthmatics StudyWithdrawnNCT00546234Phase 4
- Effects of Salmeterol on Walking Capacity in Patients With COPDCompletedNCT00525564Phase 4
- Successful Control and Clinical Effectiveness Of SERETIDE(Salmeterol/Fluticasone Propionate) Study In Asthma.(SUCCESS)CompletedNCT00480649Phase 4
- Childhood Asthma Research and Education (CARE) Network Trial - Montelukast or Azithromycin for Reduction of Inhaled Corticosteroids in Childhood Asthma (MARS)TerminatedNCT00471809Phase 4
- Safety And Efficacy Of GSK233705 Plus Salmeterol Compared With 2 Active Comparators And Placebo In Subjects With Chronic Obstructive Pulmonary Disease (COPD)CompletedNCT00422604Phase 2
- Shortness Of Breath Questionnaire Validation StudyWithdrawnNCT00411372Phase 3
- Study Of Airway Physiology In Adults. SERETIDE DISKUS® Inhaler and FLIXOTIDE® Inhaler Are Trademarks of GSK Croup of Companies.CompletedNCT00370591Phase 4
- Spacer Comparison In Adult AsthmaticsCompletedNCT00369993Phase 2
- Repeat Dose Study of Fluticasone Propionate/Salmeterol Versus Fluticasone Propionate + Salmeterol In AsthmaticsCompletedNCT00364442Phase 1
- Study Investigating Repeat Doses Of A New Medication (GSK159797) In Asthmatic PatientsCompletedNCT00358488Phase 2
- Chronic Obstructive Pulmonary Disease Endpoints StudyCompletedNCT00358358Phase 4
- ADVAIR DISKUS® (Fluticasone Propionate/Salmeterol) Inhaler Versus SEREVENT DISKUS® (Salmeterol) Inhlaer On Inflammatory Cells And Markers In Chronic Obstructive Pulmonary Disease. ADVAIR DISKUS® and SEREVENT DISKUS® Inhalers Are Trademarks of the GSK Group of Companies.TerminatedNCT00346749Phase 4
- Influence Of Different Airflow Resistances On Drug Effect Of 50μg Salmeterol And 6 μg FormoterolCompletedNCT00327353Phase 4
- Viapaed Study In Children And Adolescents With AsthmaCompletedNCT00315744Phase 4
- Study Of Patients With Allergic Rhinitis And AsthmaCompletedNCT00296530Phase 4
- A Multiple Dose Comparison of Tiotropium Inhalation Capsules and Salmeterol Inhalation Aerosol.CompletedNCT00274560Phase 3
- A Comparison of the Effects of Tiotropium Inhalation qd and Salmeterol Inhalation Bid on Arterial Blood Gases.CompletedNCT00274534Phase 3
- Study In Asthma ControlTerminatedNCT00273026Phase 4
- Survival Of Subjects With Chronic Obstructive Pulmonary Disease (COPD)CompletedNCT00268216Phase 3
- Pilot Study Comparing Tiotropium (Spiriva) to Salmeterol (Serevent) Plus Fluticasone (Flixotide) in Chronic Obstructive Pulmonary Disease (COPD)CompletedNCT00239499Phase 4
- Study In Airway Physiology In Children SERETIDE DISKUS ® Inhlaer and FLIXOTIDE® Inhaler Are Trademarks of GSK Group of Companies.CompletedNCT00169546Phase 4
- ADVAIR® DISKUS® Inhaler (Fluticasone Propionate/Salmeterol) Versus SEREVENT® DISKUS® Inhaler (Salmeterol) For The Treatment Of Chronic Obstructive Pulmonary Disease Exacerbations. ADVAIR® DISKUS® Inhaler and SEREVENT® DISKUS® Inhaler Are Trademarks of the GSK Group of Companies.CompletedNCT00144911Phase 4
- A Study Measuring Asthma Control In Pediatric And Adolescent Subjects Whose Asthma Is Worsened By Activity Or ExerciseCompletedNCT00118690Phase 4
- A Pilot Study of the Mechanism of Synergism Between FP and Salmeterol in Preventing COPD ExacerbationsCompletedNCT00116402Phase 1
- Advair® DISKUS® Versus Serevent® DISKUS® For Chronic Obstructive Pulmonary Disease ExacerbationsCompletedNCT00115492Phase 4
- Study Of Asthma And Genetics In Patients To Be Treated With Fluticasone Propionate/Salmeterol Or Salmeterol XinafoateCompletedNCT00102882Phase 4
- Study Of Asthma In Patients Of African DescentCompletedNCT00102765Phase 4
- A Multi-Centered Study of the Long-Term Effect of Salmeterol and Albuterol in Cystic FibrosisSuspendedNCT00005110Not applicable